Philippe Maitre

The Olayan Group operates as a diversified enterprise that engages in trading, manufacturing, services and investments sectors. It manages commercial and industrial operations in Saudi Arabia through its subsidiary Olayan Financing Company. The firm’s investment team focuses on public and private equities, real estate, fixed income securities, and other specialized assets. It operates through its offices located in Europe, Saudi Arabia and the United States. The company was founded by Suliman S. Olayan in 1947 and is headquartered in Riyadh, Saudi Arabia.

Invus Public Equities Advisors LLC is an investment advisory firm headquartered in New York City. The firm was founded by Raymond Debbane in 1985 and is a subsidiary of The Invus Group LLC. Invus Public Equities Advisors serves as the general partner of Invus Public Equities, L.P.

Life Generation Ltd. provides technical and vocational secondary education services. The private company is based in London, UK.

Orthobond Corp. develops chemicals to help facilitate better material surface bonding. It offers a technology based on self-assembled monolayers of phosphonate (SAMP) and osteoconductive self-assembled monolayer of phosphonate surface modification that elicits a biological response on inorganic implants without the use of a biologic. The company was founded by Gregory E. Lutz and Jeffery Schwartz in 2004 and is headquartered in North Brunswick, NJ.

The Invus Group LLC is an Independent Venture Capital firm founded in 1985 by Raymond Debbane. The Invus Group LLC is headquartered in New York, US with additional office in Paris.

ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.

Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France.

Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France.

AlchiMedics SA specializes in coating technologies via electrografting. Its products enables covalent adhesion of nano to micrometric polymer-based layers on surfaces. The firm designs, develops and implements electro-grafting technology for implantable biomedical applications. The company was founded in 2007 and is headquartered in Grenoble, France.

National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC.

The National Science Foundation supports fundamental science and engineering researches. It offers services to people in all scientific and engineering disciplines. The firm focuses on the promotion and progress of science to advance the national health, prosperity and welfare. The company was founded in 1950 and is headquartered in Arlington, VA.

MCNC, Inc. is a non-profit company based in Durham, NC. The company is a team of innovators, collaborators, and creative thinkers who provide high-end services to the community.

La Jolla Playhouse, Inc. provides educational opportunities for children, teens, and adults interested in theatre arts. The company was founded by Gregory Peck, Dorothy McGuire, and Mel Ferrer in 1947 and is headquartered in La Jolla, CA.

Institute of the Americas promotes cooperation between the public and private sectors to improve the economic, political, and social well-being of people in the Americas. Its programs are focused on energy, healthcare, telecommunication, information technology, and water. It was founded in 1983 and is headquartered in La Jolla, CA.

Founded in 1946 by Camille Dreyfus, the Camille and Henry Dreyfus Foundation, Inc. is a non-for-profit corporation located in New York City

Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.

Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach.